Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90100, Songkhla, Thailand.
Bioactivity Testing Center, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90100, Songkhla, Thailand.
Sci Rep. 2024 May 31;14(1):12531. doi: 10.1038/s41598-024-63505-x.
Binding affinity is an important factor in drug design to improve drug-target selectivity and specificity. In this study, in silico techniques based on molecular docking followed by molecular dynamics (MD) simulations were utilized to identify the key residue(s) for CSF1R binding affinity among 14 pan-tyrosine kinase inhibitors and 15 CSF1R-specific inhibitors. We found tryptophan at position 550 (W550) on the CSF1R binding site interacted with the inhibitors' aromatic ring in a π-π way that made the ligands better at binding. Upon W550-Alanine substitution (W550A), the binding affinity of trans-(-)-kusunokinin and imatinib to CSF1R was significantly decreased. However, in terms of structural features, W550 did not significantly affect overall CSF1R structure, but provided destabilizing effect upon mutation. The W550A also did not either cause ligand to change its binding site or conformational changes due to ligand binding. As a result of our findings, the π-π interaction with W550's aromatic ring could be still the choice for increasing binding affinity to CSF1R. Nevertheless, our study showed that the increasing binding to W550 of the design ligand may not ensure CSF1R specificity and inhibition since W550-ligand bound state did not induce significantly conformational change into inactive state.
结合亲和力是药物设计中提高药物靶标选择性和特异性的一个重要因素。在这项研究中,我们使用基于分子对接的计算技术,随后进行分子动力学(MD)模拟,以确定 14 种泛酪氨酸激酶抑制剂和 15 种 CSF1R 特异性抑制剂中与 CSF1R 结合亲和力相关的关键残基。我们发现 CSF1R 结合位点上的色氨酸 550 位(W550)与抑制剂的芳环以π-π相互作用,使配体更好地结合。当 W550 突变为丙氨酸(W550A)时,反式-(-)-kusunokinin 和伊马替尼与 CSF1R 的结合亲和力显著降低。然而,从结构特征来看,W550 并没有显著影响 CSF1R 的整体结构,但突变会产生不稳定的影响。W550A 也不会导致配体改变其结合位点或由于配体结合而发生构象变化。根据我们的研究结果,与 W550 的芳环形成π-π相互作用仍然是增加与 CSF1R 结合亲和力的选择。然而,我们的研究表明,设计配体与 W550 的结合增加可能并不能确保 CSF1R 的特异性和抑制作用,因为 W550-配体结合状态并没有诱导明显的构象变化进入无活性状态。